NovoCure
NVCR
304 hedge funds and large institutions have $6.34B invested in NovoCure in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 94 increasing their positions, 105 reducing their positions, and 43 closing their positions.
12% more capital invested
Capital invested by funds: $5.64B → $6.34B (+$692M)
2.47% more ownership
Funds ownership: 77.16% → 79.63% (+2.5%)
4% less funds holding
Funds holding: 317 → 304 (-13)
10% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 105
19% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 43
27% less call options, than puts
Call options by funds: $76.8M | Put options by funds: $105M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$226M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$83.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$26.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.1M |
| 5 |
Bank of New York Mellon
New York
|
+$6.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIC
Hartline Investment Corp
Winnetka,
Illinois
|
-$58M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$27.4M |
| 3 |
Jane Street
New York
|
-$21.3M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$15.8M |
| 5 |
Two Sigma Investments
New York
|
-$9.54M |
NVCR Hedge Fund Activity: Q3 2022 in Review
304 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2022, worth a combined $6.34B — up 12% from $5.64B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of NVCR and 35 opened new positions — a net loss of 8 holders — while 105 trimmed existing stakes and 94 added.
The largest buyer was Fidelity Investments, adding an estimated $226M. The largest seller was Hartline Investment Corp, exiting entirely with an estimated $58M sold.
- 304 institutional investors held NovoCure (NVCR) as of Q3 2022, down from 317 in Q2 2022.
- Funds reported $6.34B of NovoCure stock for Q3 2022, up 12% quarter-over-quarter.
- 35 funds opened new NovoCure positions in Q3 2022 and 43 closed out, a net change of -8 holders.
- The largest NovoCure buyer in Q3 2022 was Fidelity Investments, an estimated $226M added.
- The largest NovoCure seller in Q3 2022 was Hartline Investment Corp, an estimated $58M sold.
Based on aggregated 13F filings for Q3 2022.